Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Molecular Therapy for Non-Alcoholic Fatty Liver Disease: Angiotensin-(1-7) Delivery via Cyclic RGD-Modified Vesicles Activates Mas Receptor to Ameliorate Fibrosis Through Autophagy and Metabolic Reprogramming.

Niu Q., Wang T., Li J., Zhao L., Cai J.

Animal Study on Face & Skin, published in FASEB J (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
FASEB J (2026)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
41524292
DOI
10.1096/fj.202502446R

Abstract (original English)

Non-alcoholic fatty liver disease (NAFLD) is a global health burden characterized by hepatic steatosis and progressive fibrosis, necessitating novel therapeutic strategies. This study investigates the molecular mechanism by which cyclic RGD peptide (cRGD)-modified adipose-derived mesenchymal stem cell (ADMSC)-derived extracellular vesicles (EVs) deliver Angiotensin-(1-7) to attenuate NAFLD-associated liver fibrosis. EVs were isolated from murine ADMSCs via ultracentrifugation, surface-modified with cRGD using EDC/NHS crosslinkers, and loaded with Angiotensin-(1-7) via an ultrasound-assisted method. The therapeutic effects were evaluated in vitro using hepatic stellate cells (LX-2) and in vivo using a high-fat diet (HFD)-induced NAFLD mouse model. Multi-omics analyses (transcriptomics, proteomics, metabolomics) were performed on liver tissues to elucidate underlying pathways. Results demonstrated that cRGD-modified EVs loaded with Angiotensin-(1-7) exhibited excellent biocompatibility and targeted liver accumulation, significantly reducing hepatic lipid accumulation, fibrosis, and serum markers of liver damage (ALT, AST). Mechanistically, Angiotensin-(1-7) activated the Mas receptor, enhancing Akt-Foxo1-dependent autophagy and fatty acid metabolism reprogramming, as confirmed by upregulation of autophagy-related proteins (LC3-II, p62) and downregulation of fibrosis markers (TGF-

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsAutophagyNon-alcoholic Fatty Liver DiseasePeptide FragmentsMiceAngiotensin IMaleProto-Oncogene MasPeptides, CyclicMesenchymal Stem Cells

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research